Wolfram Brugger

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Medicine, Oncology, Pharmacology +6

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh et al. · The Lancet Oncology · 2010 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Steffen Walter, Toni Weinschenk, Arnulf Stenzl et al. · Nature Medicine · 2012 · 784 citations

Medicine, Immunology, Oncology +17

The Chemokine Receptor CXCR-4 Is Expressed on CD34+Hematopoietic Progenitors and Leukemic Cells and Mediates Transendothelial Migration Induced by Stromal Cell-Derived Factor-1

Robert Möhle, Frank Bautz, Shahin Rafii et al. · Blood · 1998 · 635 citations

Life Sciences, Cell Biology, Hematology +17

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

Peter Brossart, Stefan Wirths, Gernot Stuhler et al. · Blood · 2000 · 540 citations

Life Sciences, Cell Biology, Immunology +14